eldecalcitol
Selected indexed studies
- Eldecalcitol for the treatment of osteoporosis. (Clin Interv Aging, 2013) [PMID:24101867]
- Eldecalcitol for sarcopenia prevention in adults with prediabetes. (Lancet Healthy Longev, 2024) [PMID:38824954]
- Eldecalcitol Inhibits LPS-Induced NLRP3 Inflammasome-Dependent Pyroptosis in Human Gingival Fibroblasts by Activating the Nrf2/HO-1 Signaling Pathway. (Drug Des Devel Ther, 2020) [PMID:33223823]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Eldecalcitol for the treatment of osteoporosis. (2013) pubmed
- Eldecalcitol for sarcopenia prevention in adults with prediabetes. (2024) pubmed
- Eldecalcitol Inhibits LPS-Induced NLRP3 Inflammasome-Dependent Pyroptosis in Human Gingival Fibroblasts by Activating the Nrf2/HO-1 Signaling Pathway. (2020) pubmed
- Eldecalcitol: a review of its use in the treatment of osteoporosis. (2011) pubmed
- Eldecalcitol replaces endogenous calcitriol but does not fully compensate for its action in vivo. (2014) pubmed
- Eldecalcitol ameliorates diabetic osteoporosis and glucolipid metabolic disorder by promoting Treg cell differentiation through SOCE. (2024) pubmed
- Eldecalcitol for the treatment of osteoporosis. (2012) pubmed
- Eldecalcitol prevents muscle loss by suppressing PI3K/AKT/FOXOs pathway in orchiectomized mice. (2022) pubmed
- Eldecalcitol: newly developed active vitamin D(3) analog for the treatment of osteoporosis. (2013) pubmed
- Eldecalcitol alleviates diabetic periodontitis by regulating macrophage efferocytosis and polarization via SOCE machinery. (2025) pubmed